Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Director Jonathan C. Fox Acquires 10,857 Shares

Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Free Report) Director Jonathan C. Fox purchased 10,857 shares of the business’s stock in a transaction dated Tuesday, December 26th. The shares were acquired at an average cost of $9.30 per share, for a total transaction of $100,970.10. Following the acquisition, the director now owns 10,857 shares of the company’s stock, valued at approximately $100,970.10. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Edgewise Therapeutics Trading Down 5.0 %

EWTX stock traded down $0.60 during trading on Thursday, hitting $11.50. The company had a trading volume of 1,614,894 shares, compared to its average volume of 237,555. The firm has a market capitalization of $729.79 million, a price-to-earnings ratio of -8.10 and a beta of -0.26. The business has a 50 day moving average of $6.97 and a 200 day moving average of $7.00. Edgewise Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $12.46.

Edgewise Therapeutics (NASDAQ:EWTXGet Free Report) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, equities analysts predict that Edgewise Therapeutics, Inc. will post -1.56 EPS for the current year.

Hedge Funds Weigh In On Edgewise Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EWTX. Goldman Sachs Group Inc. raised its stake in shares of Edgewise Therapeutics by 132.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,753,849 shares of the company’s stock worth $13,592,000 after buying an additional 999,710 shares in the last quarter. Granahan Investment Management LLC acquired a new position in Edgewise Therapeutics during the first quarter worth about $4,894,000. Ensign Peak Advisors Inc bought a new stake in Edgewise Therapeutics in the first quarter worth about $6,427,000. Vanguard Group Inc. lifted its holdings in Edgewise Therapeutics by 42.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,751,845 shares of the company’s stock valued at $17,239,000 after acquiring an additional 525,277 shares during the last quarter. Finally, Bank of Montreal Can acquired a new stake in Edgewise Therapeutics in the 2nd quarter valued at about $2,700,000.

Wall Street Analyst Weigh In

Separately, Wedbush lowered their target price on Edgewise Therapeutics from $27.00 to $23.00 and set an “outperform” rating on the stock in a research report on Friday, November 10th.

View Our Latest Stock Report on Edgewise Therapeutics

About Edgewise Therapeutics

(Get Free Report)

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

Further Reading

Insider Buying and Selling by Quarter for Edgewise Therapeutics (NASDAQ:EWTX)

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.